Gland Pharma Stock Screener | Share Price & Fundamental Analysis
GLAND
Pharmaceuticals
Share Price NSE
₹1728.50
▲
12.10 (0.70%)
Share Price BSE
₹1729.20
▲
15.25 (0.89%)
Track Gland Pharma share price live with TickJournal's free stock screener.
Analyze Gland Pharma share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Gland Pharma Market Cap
₹27,820.77 Cr.
GLAND P/E Ratio (TTM)
33.19
Gland Pharma P/B Ratio
2.94
EPS (TTM)
₹42.40
Dividend Yield
1.05%
Debt to Equity
0.04
GLAND 52 Week High
₹2102.10
Gland Pharma 52 Week Low
₹1393.75
Operating Margin
24.00%
Profit Margin
12.73%
GLAND Revenue (TTM)
₹1,469.00
EBITDA
₹392.00
Net Income
₹187.00
Total Assets
₹11,225.00
Total Equity
₹9,151.00
Gland Pharma Share Price History - Stock Screener Chart
Screen GLAND historical share price movements with interactive charts. Analyze price trends and patterns.
Gland Pharma Company Profile - Fundamental Screener
Screen Gland Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for GLAND shares.
Gland Pharma Limited is an Indian generic injectables manufacturer specializing in sterile injectables, oncology, and ophthalmic products. Founded in 1978, the company operates primarily on a B2B model, selling products in over 60 countries. It has 8 manufacturing facilities in India, including 4 for finished formulations and 3 for APIs....more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
SRINIVAS SADU
ISIN
INE068V01023
Website
https://www.glandpharma.com
Gland Pharma Balance Sheet Screener
Screen GLAND balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total Assets | 11,225 | 10,661 | 8,778 | 7,834 | 6,496 | 4,086 |
| Current Assets | 6,783 | 5,645 | 6,901 | 5,852 | 5,124 | 2,846 |
| Fixed Assets | 4,147 | 3,947 | 1,571 | 1,502 | 954 | 968 |
| Liabilities | ||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 509 | 539 | 90 | 94 | 80 | 81 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||
| Total Equity | 9,151 | 8,724 | 7,959 | 7,158 | 5,903 | 3,646 |
| Share Capital | 17 | 17 | 17 | 16 | 16 | 16 |
| Reserves & Surplus | 9,134 | 8,707 | 7,942 | 7,141 | 5,887 | 3,631 |
Gland Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Gland Pharma income statement and profit fundamentals.
Analyze GLAND quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Gland Pharma share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,469 | 1,563 | 1,571 | 1,759 | 1,580 | 1,453 | 1,466 | 1,443 | 824 | 1,246 | 1,427 | 1,583 | 1,168 | 931 | 1,110 |
| Expenses | 1,077 | 1,138 | 1,173 | 1,285 | 1,179 | 1,137 | 1,109 | 1,024 | 673 | 915 | 1,049 | 1,189 | 755 | 587 | 748 |
| EBITDA | 392 | 425 | 398 | 474 | 401 | 316 | 357 | 418 | 151 | 332 | 377 | 394 | 414 | 344 | 363 |
| Operating Profit % | 24.00% | 24.00% | 21.00% | 24.00% | 23.00% | 19.00% | 21.00% | 26.00% | 14.00% | 24.00% | 24.00% | 23.00% | 32.00% | 32.00% | 28.00% |
| Depreciation | 96 | 101 | 106 | 108 | 93 | 92 | 94 | 96 | 38 | 65 | 81 | 105 | 31 | 35 | 37 |
| Interest | 7 | 12 | 8 | 4 | 10 | 6 | 6 | 23 | 2 | 5 | 6 | 5 | 2 | 1 | 2 |
| Profit Before Tax | 288 | 313 | 284 | 362 | 298 | 218 | 257 | 299 | 111 | 261 | 290 | 283 | 381 | 309 | 324 |
| Tax | 102 | 97 | 100 | 101 | 106 | 75 | 93 | 95 | 33 | 67 | 96 | 91 | 95 | 79 | 83 |
| Net Profit | 187 | 216 | 184 | 262 | 192 | 144 | 164 | 205 | 79 | 194 | 194 | 192 | 286 | 229 | 241 |
| EPS | 11.32 | 13.08 | 11.15 | 15.87 | 11.68 | 8.73 | 9.93 | 12.42 | 4.78 | 11.79 | 11.78 | 11.65 | 17.40 | 13.93 | 14.65 |
Gland Pharma Cash Flow Screener - Liquidity Fundamentals
Screen GLAND cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March |
|---|---|---|---|---|---|---|
| Operating Activities | 915 | 997 | 364 | 791 | 605 | 701 |
| Investing Activities | 1,718 | -1,749 | 1,211 | -999 | -1,520 | -761 |
| Financing Activities | -434 | -799 | 15 | 35 | 1,239 | -7 |
| Net Cash Flow | 2,199 | -1,552 | 1,590 | -174 | 323 | -67 |
Gland Pharma Shareholding Pattern Screener
See Gland Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Gland Pharma promoter holding and ownership changes for GLAND on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 51.83% | 51.83% | 51.83% | 51.83% | 57.86% | 51.83% | 51.83% | 51.83% |
| FII Holding | 6.90% | 7.39% | 7.91% | 7.58% | 3.59% | 6.88% | 4.47% | 5.04% |
| DII Holding | 33.27% | 32.85% | 32.64% | 32.98% | 25.23% | 32.83% | 35.37% | 34.80% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 2.99% | 2.91% | 2.57% | 2.57% | 3.28% | 3.33% | 3.28% | 3.30% |
| Other Holding | 5.01% | 5.02% | 5.06% | 5.04% | 10.04% | 5.12% | 5.04% | 5.04% |
| Shareholder Count | 113,788 | 110,671 | 97,151 | 94,578 | 122,375 | 122,665 | 122,358 | 121,075 |
Gland Pharma Share Dividend Screener - Share Yield Analysis
Check Gland Pharma dividend history with payout and yield data.
View Gland Pharma dividend details including ex-dates and amounts for GLAND stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹18.00 | 1.06% |
| 2024-March | ₹20.00 | 1.26% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Gland Pharma Stock Index Membership
See which indices include Gland Pharma stock.
Check GLAND index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX BSEIPO
BSE INDEX LMI250
BSE INDEX MID150
BSE INDEX MIDCAP
BSE INDEX MSL400
NIFTY 500
NIFTY LARGEMID250
NIFTY MIDCAP 150
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MNC
NIFTY PHARMA
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
Gland Pharma Market Events Screener - Corporate Actions
Get Gland Pharma corporate actions including splits, bonuses, and buybacks.
Check Gland Pharma stock events that may affect GLAND share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-01-28 | 2026-01-28 | Quarterly Result Announcement | NA | -1.36% |
| 2025-11-03 | 2025-11-03 | Quarterly Result Announcement | NA | 0.59% |
| 2025-08-28 | 2025-08-28 | Annual General Meeting | NA | 29.92% |
| 2025-08-14 | 2025-08-14 | Dividend | ₹ 18.00 /share | 31.41% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | -0.90% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 4.61% |
| 2025-02-03 | 2025-02-03 | Quarterly Result Announcement | NA | -8.51% |
| 2024-11-04 | 2024-11-04 | Quarterly Result Announcement | NA | -1.82% |
| 2024-08-30 | 2024-08-30 | Annual General Meeting | NA | 2.71% |
| 2024-08-16 | 2024-08-16 | Dividend | ₹ 20.00 /share | 8.78% |
Gland Pharma Competitors Screener - Peer Comparison
Screen GLAND competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 406,351 | 37.86 | 54,729 | 9.71% | 10,980 | 37.98 |
| Divis Laboratories | 155,472 | 63.26 | 9,712 | 18.67% | 2,191 | 33.24 |
| Torrent Pharmaceuticals | 134,945 | 61.20 | 11,539 | 6.99% | 1,911 | 32.75 |
| Lupin | 103,954 | 22.26 | 22,910 | 13.74% | 3,306 | 47.35 |
| Dr Reddys Laboratories | 101,601 | 18.27 | 33,741 | 16.73% | 5,725 | 39.36 |
| Cipla | 96,320 | 21.31 | 28,410 | 7.12% | 5,291 | 26.86 |
| Zydus Life Science | 86,964 | 17.29 | 23,511 | 18.55% | 4,615 | 41.42 |
| Mankind Pharma | 82,499 | 45.81 | 12,744 | 20.90% | 2,007 | 41.40 |
| Aurobindo Pharma | 77,462 | 22.37 | 32,346 | 9.43% | 3,484 | 64.38 |
| Alkem Laboratories | 62,867 | 25.87 | 13,458 | 3.70% | 2,216 | 42.54 |
Gland Pharma Company Announcements - News Screener
Screen GLAND latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-01 | Closure of Trading Window | - |
| 2026-03-18 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-09 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-06 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-03-04 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-03 | Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO) | - |
| 2026-03-03 | Announcement under Regulation 30 (LODR)-Issue of Securities | - |
| 2026-02-25 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-20 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-18 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-02-09 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-06 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-03 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-01 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-29 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-01-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-01-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |